Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice

Virology Journal

Volumn 8, Issue , 2011, Pages

  Zhang, Shuo ^a   Liang, Mifang ^a   Gu, Wen ^a   Li, Chuan ^a   Miao, Fang ^a   Wang, Xiaofang ^a   Jin, Cong ^a   Zhang, Li ^a   Zhang, Fushun ^a   Zhang, Quanfu ^a   Jiang, Lifang ^b   Li, Mengfeng ^b   Li, Dexin ^a  

^a National Institute for Communicable Disease Control and Prevention   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Dengue virus; Vaccine; VLP

Indexed keywords

DENGUE VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIROSOME VACCINE; VIRUS ANTIBODY;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENGUE VIRUS 4; FEMALE; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PLASMID; VACCINATION; VACCINE PRODUCTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL LINE; DENGUE VIRUS; GENETICS; HUMAN; IMMUNOLOGY; METHODOLOGY;

DENGUE VIRUS; MAMMALIA; MUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VACCINES, VIROSOME;

EID: 79959679039     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-333     Document Type: Article

References (36)

1. Development of a novel DNA SynCon tetravalent dengue vaccine that elicitsimmune responses against four serotypes. MP Ramanathan YC Kuo BH Selling,, et al. Vaccine 2009 27 6444 53 10.1016/j.vaccine.2009.06.061 19580892
2. Centers for Disease Control and Prevention (CDC) DoV-bID-DF. http://cdc.gov/ncidod/dvbid/dengue [cited]
3. Flavivirus genome organization, expression, and replication. TJ Chambers CS Hahn R Galler,, et al. Ann Rev Microbiol 1990 44 649 88 10.1146/annurev.mi. 44.100190.003245
4. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. A Sabchareon J Lang P Chanthavanich,, et al. Am J Trop Med Hyg 2002 66 264 72 12139219 (Pubitemid 34756095)
5. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. A Sabchareon J Lang P Chanthavanich,, et al. Pediatr Infect Dis J 2004 23 99 109 10.1097/01.inf.0000109289.55856.27 14872173 (Pubitemid 38222779)
6. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. R Edelman SS Wasserman SA Bodison,, et al. Am J Trop Med Hyg 2003 69 48 60 14740955
7. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. BL Innis KH Eckels, Am J Trop Med Hyg 2003 69 1 4 14756126
8. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine. Jun-ichi Imoto Eiji Konishi, Vaccine 2007 25 1076 84 10.1016/j.vaccine.2006.09.059 17084490 (Pubitemid 44937449)
9. Progress towards a dengue vaccine. Daniel P Webster Jeremy Farrar Sarah Rowland-Jones, The Lancet Infectious Diseases 2009 9 678 87 10.1016/S1473- 3099(09)70254-3 19850226
10. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. JM Galarza T Latham A Cupo, Viral Immunol 2005 18 1 244 51 10.1089/vim.2005.18.244 15802970 (Pubitemid 40586463)
11. Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice. C Li F Liu M Liang Q Zhang,, et al. Vaccine 2010 28 4294 4300 10.1016/j.vaccine.2010.04.025 20433802
12. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. J Weber R Cheinsong-Popov D Callow,, et al. Vaccine 1995 13 831 4 10.1016/0264-410X(94)00061-Q 7483805
13. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. C Sedlik M Saron J Sarraseca,, et al. Proc Natl Acad Sci USA 1997 94 7503 8 10.1073/pnas.94.14.7503 9207121 (Pubitemid 27345345)
14. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. K Murata M Lechmann M Qiao,, et al. Proc Natl Acad Sci USA 2003 100 6753 8 10.1073/pnas.1131929100 12748380 (Pubitemid 36666652)
15. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Pinto A Ligia Castle,, et al. Vaccine 2005 23 3555 64 10.1016/j.vaccine.2005.01.146 15855014
16. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Wataru Akahata Zhi-Yong Yang Hanne Andersen,, et al. Nature Medicine 2010 16 334 8 10.1038/nm.2105 20111039
17. Flavivirus DNA vaccines: current status and potential. GJ Chang BS Davis AR Hunt,, et al. Ann NY Acad Sci 2001 951 272 85 11797784 (Pubitemid 34060051)
18. DNA vaccines for flaviviruses. R Putnak K Porter C Schmaljohn, Adv Virus Res 2003 61 445 68 14714440 (Pubitemid 137640956)
19. Flaviviridae: the viruses and their replication. BD Lindenbach CM Rice, Fields Virology Philadelphia: Lippincott Williams & Willkins, Knipe DM, Howley PM, 4 2001 991 1041
20. A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. GJ Chang AR Hunt B Davis, J Virol 2000 74 4244 52 10.1128/JVI.74.9.4244-4252.2000 10756038 (Pubitemid 30214431)
21. Inefficient Signalase Cleavage Promotes Efficient Nucleocapsid Incorporation into Budding Flavivirus Membranes. Mario Lobigs Eva Lee, J Virol 2004 78 178 86 10.1128/JVI.78.1.178-186.2004 14671099 (Pubitemid 37549730)
22. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans. CH Hoke Jr FJ Malinoski KH Eckels,, et al. Am J Trop Med Hyg 1990 43 219 26 2389825 (Pubitemid 20268892)
23. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. R Edelman CO Tacket SS Wasserman,, et al. J Infect Dis 1994 170 1448 55 10.1093/infdis/170.6. 1448 7995984 (Pubitemid 24369904)
24. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice. I Staropoli MP Frenkiel F Megret,, et al. Vaccine 1997 15 1946 54 10.1016/S0264-410X(97)00128-X 9413106 (Pubitemid 27504692)
25. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. M Simmons WM Nelson SJ Wu,, et al. Am J Trop Med Hyg 1998 58 655 62 9598457 (Pubitemid 28237267)
26. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. M Bray R Men CJ Lai, J Virol 1996 70 4162 6 8648761 (Pubitemid 26157401)
27. Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. AG Pletnev R Men, Proc Natl Acad Sci USA 1998 95 1746 51 10.1073/pnas.95.4.1746 9465088 (Pubitemid 28103465)
28. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. T Kochel SJ Wu K Raviprakash,, et al. Vaccine 1997 15 547 52 10.1016/S0264-410X(97)00215-6 9160523 (Pubitemid 27188622)
29. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. GJ Chang AR Hunt DA Holmes,, et al. Virology 2003 306 170 80 10.1016/S0042-6822(02)00028-4 12620809 (Pubitemid 36293407)
30. A strong endoplasmic reticulum retention signal in the stem-anchor region of envelope glycoprotein of dengue virus type 2 affects the production of virus-like particles Virology. SC Hsieh IJ Liu CC King,, et al. 2008 374 2 338 50
31. The length of and nonhydrophobic residues in the transmembrane domain of dengue virus envelope protein are critical for its retention and assembly in the endoplasmic reticulum. SC Hsieh WY Tsai WK Wang, J Virol 2010 84 4782 97 10.1128/JVI.01963-09 20181718
32. Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein. DE Purdy GJ Chang, Virology 2005 333 239 250 10.1016/j.virol.2004.12.036 15721358 (Pubitemid 40250108)
33. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. J Pradeep Babu Priyabrata Pattnaik Nimesh Gupta,, et al. Vaccine 2008 26 4655 63 10.1016/j.vaccine.2008.07.006 18640168
34. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. R Schirmbeck K Melber A Kuhrober,, et al. J Immunol 1994 152 1110 9 8301120 (Pubitemid 24134336)
35. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. HL Greenstone JD Nieland KE de Visser,, et al. Proc Natl Acad Sci USA 1998 95 4 1800 5 10.1073/pnas.95.4. 1800 9465097 (Pubitemid 28103474)
36. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. I Valdés L Bernardo L Gil,, et al. Virology 2009 394 249 58 10.1016/j.virol.2009.08.029 19783271